Sun Pharma expects 18-20% FY13 sales growth

Sun Pharmaceutical expects 18-20% sales growth in the current fiscal year that started in April, Managing Director Dilip Shanghvi said in an earnings conference call on Wednesday.
  • Language
  • App
  • Subscriptions
  • Specials
  • Sign-In
  • Register
GeStepAhead GrowMyMoney IThe Winning Leap SME Special
Moneycontrol

Home » News » Earnings » Results- Company Press Conference

May 30, 2012, 04.05 PM | Source: CNBC-TV18

Sun Pharma expects 18-20% FY13 sales growth

Sun Pharmaceutical expects 18-20% sales growth in the current fiscal year that started in April, Managing Director Dilip Shanghvi said in an earnings conference call on Wednesday.

Like this story, share it with millions of investors on M3

Sun Pharma expects 18-20% FY13 sales growth

Sun Pharmaceutical expects 18-20% sales growth in the current fiscal year that started in April, Managing Director Dilip Shanghvi said in an earnings conference call on Wednesday.

Post Your Comments

Share Cancel

Dilip Shanghvi, Sun Pharmaceutical
Sun Pharmaceutical  expects 18-20% sales growth in the current fiscal year that started in April, Managing Director Dilip Shanghvi said in an earnings conference call on Wednesday.

The drug maker posted a spectacular 85% jump in March quarter net profit at Rs 820 crore, driven by strong sales of its Israeli unit Taro.

However, the company said the increase in Taro sales will not be sustainable going forward as these were largely a result of price increases on select products in the US market.

Net sales of the company for the quarter ended March 31, 2012 stood at Rs 2,330 crore, up nearly 60% from the corresponding period previous fiscal.

Commenting on the quarter gone by, Dilip Shanghvi, MD of Sun Pharma said, "Performance this year has been in line with our expectations and marginally ahead of our recently revised sales guidance. Though the year has seen a couple of non-recurring elements, the underlying business remains stead across all segments and capable of delivering long-term sustainable growth."

The company sees FY13 capex at Rs 500 crore with the research and development spend at 6-8% of net sales. It plans to file 25 ANDAs in US in FY13.

Interestingly, Dilip Shanghvi has stepped down from the chairmanship, while continuing to remain the managing director of the company.

According to the company press release, Israel Makov has been appointed as the chairman of the Sun Pharma at meeting of the Board of Directors of the company held on May 29, 2012. Makov also gets a seat on the board of directors of Sun Pharma.

Makov is the former President and CEO of Teva Pharmaceutical Industries (2002-2007), widely credited with Teva's emergence as a global company and a world leader in generic pharmaceuticals.

Buy, Hold, Sell ? Hear it first on M3
Sun Pharma expects 18-20% FY13 sales growth

See all

Get started using your favorite social network

or

Login using moneycontrol ID

Username
Password

Need help logging in? Reset password.

Don´t have an account? Sign Up

Get started using your favorite social network

or

Simply sign up using this short form

* mandatory

UserName*

Username should be atleast 4 character

Password*

Password should be 8 or more characters,
atleast 1 number, 1 symbol & 1 upper case letter

Alert

Your Password should contain
  • 8 or more characters
  • At least 1 number
  • At least 1 symbol
  • At least 1 upper case letter
Confirm Password*
Email
Already have an account? Login